very poor(or with ill intention) AAIC 2018 web site:
I went to on alz.org site; then AAIC 2018 page.
You do not see "Anavex" under "PRESS RELEASE" because Anavex is under title of
"Study Shows Intensive Blood Pressure Control Reduces Risk of Mild Cognitive Impairment (MCI) and the Combined Risk of MCI and Dementia"
And when you open the page you will see subtitle at the top:
– Plus: – Genomic Analysis of Alzheimer’s Study May Enable a Precision Medicine Approach –
What a Joke! They had tried to hide name of "Anavex" so hard!!!
Then the article below about Anavex and Precision Medicine:
Genomic Analysis of Phase 2a Alzheimer’s Study with ANAVEX®2-73 May Enable a Precision Medicine Approach
“Precision medicine involves giving the right therapy to the right patient at the right time, customized to his or her specific biological makeup,” says Professor Harald Hampel, MD, PhD, MA, MSc, AXA Research Fund & Sorbonne University Excellence Chair, Department of Neurology, Sorbonne University, Paris.
Precision medicine emphasizes the customization and individualization of healthcare, with treatments and practices tailored to the specific patient’s situation and needs, often taking into account genes, environment, and lifestyle. Sometimes called personalized medicine, it is a common approach in cancer and respiratory diseases.
At AAIC 2018, Hampel and colleagues reported results of an innovative attempt to move a step closer to precision medicine in Alzheimer’s therapy trials. Anavex Life Sciences (AVXL) conducted a 57-week Phase 2a study with ANAVEX®2-73, a selective sigma-1 receptor agonist, in 32 people with mild to moderate Alzheimer’s disease and analyzed the entire genome DNA and RNA of all study participants, resulting in the analysis of 33,311 genes and 860 pathways.
The company identified several genetic variants that impacted response to the drug, including SIGMAR1, which is ANAVEX®2-73’s target, and COMT, a gene involved in memory function. They found further that excluding people with these variants (~20% of the study group) — leaving about 80% of the population — resulted in improved scores on gold standard tests of cognition (MMSE) and activities of daily living (ADCS-ADL) (p<0.05).
Including participants with milder disease (baseline MMSE≥20) and excluding those with a SIGMAR1 variant resulted in improvement of 1.7 MMSE and 3.9 ADCS-ADL at week 57.
The additional exclusion of the COMT variant resulted in a score improvement of 2.0 MMSE and 4.9 ADCS-ADL at week 57.
“This study represents an exciting step forward, away from the ‘magic bullet, one-size-fits-all’ drug development in Alzheimer’s, following the targeted therapy successes in the field of oncology,” Hampel said. “Our vision is that a precision medicine approach will allow us to more precisely treat and prevent key features of the cause and progression of Alzheimer’s. We are intrigued that several studies with this novel approach are now planned or underway.”
According to the company, these patient selection markers will be implemented in an upcoming Phase 2b/3 study of ANAVEX®2-73.
